G
G

GSK


Nieuws

Moderna data puts the spotlight on RSV vaccines under development

FACTBOX-Moderna data puts the spotlight on RSV vaccines under development Adds details on Moderna vaccine Jan 18 (Reuters) - Moderna Inc MRNA.O said on Tuesday its respiratory syncytial virus (RSV) vaccine was highly effective in preventing at least two symptoms of infections in older adults in a late-stage trial, as drugmakers race to develop a shot against the virus.
A
G
P
S
S

Moderna says RSV vaccine 84% effective at preventing symptoms in older adults

FACTBOX-Moderna data puts the spotlight on RSV vaccines under development Adds details on Moderna vaccine Jan 18 (Reuters) - Moderna Inc MRNA.O said on Tuesday its respiratory syncytial virus (RSV) vaccine was highly effective in preventing at least two symptoms of infections in older adults in a late-stage trial, as drugmakers race to develop a shot against the virus.
A
G
P
S
S

Some bloodstream infection bacteria grew resistant to last-resort drugs in 2020 - WHO

By Natalie Grover LONDON, Dec 9 (Reuters) - Increased drug resistance in bacteria causing bloodstream infections, including against last-resort antibiotics, was seen in the first year of the coronavirus pandemic, a World Health Organization report based on data from 87 countries in 2020 showed. The overuse and/or misuse of antibiotics has helped microbes to become resistant to many treatments, while the pipeline of replacement therapies in development is alarmingly sparse.
G

European shares fall for fourth day on growth worries

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window) * STOXX 600 falls for the fourth straight day * Euro zone economic growth revised up * Dip in crude prices drags energy stocks lower * GSK, Sanofi shares boost healthcare sector * Airbus falls on dropping delivery forecast By Amruta Khandekar and Bansari Mayur Kamdar Dec 7 (Reuters) - European shares fell for a fourth straight session on Wednesday, with investors on edge as global recession fea
A
G
S
E
F
G

UK Stocks-Factors to watch on Dec 7

Dec 7 (Reuters) - Britain's FTSE 100 .FTSE index is seen inching higher at open on Wednesday, with futures FFIc1 up 0.05%. * MITCHELLS & BUTLERS: Pub and restaurant group Mitchells & Butlers Plc MAB.L flagged challenges arising from surging energy and labour costs. * MOONPIG: Moonpig MOONM.L lowered its annual revenue forecast and reported lower first-half profit.
E
G
M
P
S
U

UK Stocks-Factors to watch on Dec 7

Dec 7 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Wednesday, with futures FFIc1 up 0.43%. * GSK: Drugmakers GSK Plc GSK.L , Pfizer Inc PFE.N , Sanofi SA SASY.PA and Boehringer Ingelheim were spared thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer. * BT: Britain's CityFibre has filed a complaint to the competition regulator against BT's Openreach.
E
G
M
U

British Business - Nov 23

Nov 23 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times A potential blockbuster blood cancer treatment Blenrep being developed by GSK Plc GSK.L is to be removed from the American market after a request from regulators. Cristiano Ronaldo has left Manchester United Plc MANU.N without receiving any compensation after the two parties agreed to rip up his contract.
B
G

UK Stocks-Factors to watch on Nov 22

Nov 22 - Britain's FTSE 100 .FTSE index is seen opening higher on Tuesday with futures FFIc1 up 0.25%. * GSK: GSK Plc GSK.L has initiated a process to withdraw the U.S. approval for its blood cancer drug Blenrep. * PETROFAC: Petrofac Ltd PFC.L appointed Tareq Kawash as the group's new chief executive officer. * BABCOCK: Babcock BAB.L posted a 5% rise in half-year operating profit and said it was focused on controlling the impact of inflation on its business as the cost of wages and materials inc
B
G
H
P
S
U

UK Stocks-Factors to watch on Nov 11

Nov 11 (Reuters) - Britain's FTSE 100 .FTSE index ticked higher on Friday and was up 0.03% as of 0909 GMT. * ECONOMY: Britain's economy shrank in the three months to September at the start of what is likely to be a lengthy recession, underscoring the challenge for finance minister Jeremy Hunt as he prepares to raise taxes and cut spending next week. * INFLATION: British finance minister Jeremy Hunt said on Friday the best way to help cash-strapped households hit by a cost of living squeeze was t
A
G
U

UK Stocks-Factors to watch on Nov 2

Nov 2 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher with futures FFIc1 up 0.22% on Wednesday. * ASHTON MARTIN: British luxury carmaker Aston Martin AML.L warned that higher costs from global supply chain and logistical disruptions would hurt its margins, and lowered its wholesale delivery volume outlook for 2022. * GSK: GSK GSK.L beat analyst expectations for its third-quarter sales and profit, months after executing a rehaul of the business with the spin-off of its consumer
G
N
U

GSK lifts 2022 forecast again after stronger than expected quarter

By Natalie Grover Nov 2 (Reuters) - GSK GSK.L on Wednesday GSK GSK.L on Wednesday smashed analysts' estimates for third-quarter earnings, driven by higher sales of its blockbuster shingles vaccine, Shingrix. This quarter, Shingrix blew past expectations by generating sales of 760 million pounds ($872.86 million) compared to the GSK-compiled consensus of 685 million pounds.
B
G
P
S

GSK lifts 2022 forecast after stronger than expected quarter

Nov 2 (Reuters) - GSK GSK.L on Wednesday beat analyst expectations for its third-quarter sales and profit, months after executing a rehaul of the business with the spinoff of its consumer health unit. The British drugmaker, now solely focused on vaccines and medicines, reported adjusted profit of 46.9 pence on sales of about 7.83 billion pounds ($9 billion), compared with a company-compiled analyst consensus of 40.1 pence on sales of 7.32 billion pounds.
G

China bars GSK from bulk-buy drug programme for 18 months

By Natalie Grover BEIJING/LONDON, Oct 31 (Reuters) - China has blocked GSK GSK.L from participating in its bulk-buy drug procurement programme focused on off-patent medicines from Oct. 31 until April 29, 2024, over quality problems with a prostate drug, the British drugmaker said on Monday. First reported by CCTV state television, the ban was imposed by authorities after a batch of GSK's prostate treatment - known chemically as dutasteride and sold under the brand name Avodart - made by a Polish
G

Global firms urge governments to require mandatory disclosures on nature

* Over 330 businesses including Danone, Nestle back call * Signatories want large companies to assess, disclose impact * Unilever sustainability chief calls for 'decisive action' By Juliette Portala Oct 26 (Reuters) - Over 330 businesses on Wednesday urged world leaders to force large companies to assess and disclose their impact on nature by 2030, ahead of the COP15 global talks on biodiversity in December.
B
D
G
N
R
H

British Business - Oct 14

Oct 14 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - BT Group BT.L and other phone operators have been given another year to strip out Huawei technology from core 5G networks to avoid causing serious disruption to customers, the government said.
B
G
N

Nestle CEO: I'm not a 'mega deal' maker

ZURICH, Sept 29 (Reuters) - Food group Nestle NESN.S is in no hurry to acquire companies given rich valuations and will stick to its traditionally cautious approach to deals, its chief executive told a conference on Thursday. "I've done hundreds of deals in my life, the largest one ever was Starbucks at 7 billion so I'm not a 'mega deal' maker," Mark Schneider said in a discussion organised by Bernstein.
G
N
S

British Business - Sept 27

Sept 27 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - Unilever plc ULVR.L is to start the search for a new chief executive officer after Alan Jope said that he intended to retire at the end of next year after five years in charge.
B
E
G
W

UK Stocks-Factors to watch on Sept 26

Sept 26 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher with futures FFIc1 up 0.51% on Monday. * UNILEVER: Unilever ULVR.L CEO Alan Jope plans to retire at the end of 2023, the maker of Dove soap and Knorr stock cubes said on Monday, roughly two months after activist investor Nelson Peltz joined the board. * GSK: GSK GSK.L named luxury fashion brand Burberry's BRBY.L Julie Brown as its new chief financial officer to succeed Iain Mackay, at a time when the British drugmaker is s
B
B
G
R
U

UK Stocks-Factors to watch on Sept 26

Sept 26 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher with futures FFIc1 up 0.28% on Monday. * GSK: British drugmaker GSK GSK.L has poached Burberry Group's BRBY.L finance chief to create a rare all-female executive leadership team, Sky News reported on Saturday. * BARCLAYS: Barclays BARC.L was sued in a proposed U.S. class action in which shareholders claimed they were defrauded in connection with the British bank's sale of $17.6 billion more debt than regulators had allowed
B
B
G
R
U

British Business - Sept 23

Sept 23 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times The asset management business of HSBC Holdings Plc HSBA.L has set out plans to cut investments in thermal coal, months after one of its former top executives caused a furore with his comments about climate change.
G
H
R



Voorwaarden

Populaire activa

Disclaimer: De entiteiten van de XM Group bieden diensten en toegang tot ons online handelsplatform op basis van uitsluitend-uitvoering, waardoor een persoon de beschikbare content op of via de website kan bekijken en/of gebruiken, zonder dat dit is bedoeld voor wijziging of uitbreiding. Dergelijk(e) toegang en gebruik vallen onder: (i) de algemene voorwaarden; (ii) risicowaarschuwingen; en de (iii) volledige disclaimer. Dergelijke content wordt daarom alleen aangeboden als algemene informatie. Wees u er daarnaast vooral van bewust dat de inhoud op ons online handelsplatform geen verzoek of aanbieding omvat om transacties op de financiële markten uit te voeren. Het beleggen op welke financiële markt dan ook vormt een aanzienlijk risico voor uw vermogen.

Alle materialen die op ons online handelsplatform worden gepubliceerd zijn bedoeld voor educatieve/informatieve doeleinden en omvatten geen – en moeten niet worden beschouwd als het bevatten van – financieel, vermogensbelastings- of handelsadvies en aanbevelingen, of een overzicht van onze handelsprijzen, of een aanbod of aanvraag van een transactie in financiële instrumenten of ongevraagde financiële promoties voor u.

Alle content van derden, alsmede content die is voorbereid door XM, zoals opinies, nieuws, onderzoeken, analyses, prijzen en andere informatie of koppelingen naar externe websites op deze website worden aangeboden op een 'zoals-ze-zijn'-basis, als algemene marktcommentaren, en vormen geen beleggingsadvies. Voor zover dat content wordt beschouwd als beleggingsonderzoek, moet u zich ervan bewust zijn en accepteren dat de content niet bedoeld was en niet is voorbereid in overeenstemming met de wettelijke vereisten die zijn opgesteld om de onafhankelijkheid van beleggingsonderzoek te bevorderen en als zodanig onder de geldende wetgeving en richtlijnen moet worden beschouwd als marketingcommunicatie. Zorg ervoor dat u onze Mededeling over niet-onafhankelijk beleggingsonderzoek en risicowaarschuwing in verband met de voorgaande informatie doorneemt en begrijpt; die kunt u hier lezen.

We gebruiken cookies om u de beste ervaring op onze website te bieden. Meer lezen of wijzig uw cookie-instellingen.

Risicowaarschuwing: Uw vermogen loopt risico. Hefboomproducten zijn mogelijk niet voor iedereen geschikt. Lees onze informatie over risico's.